Brief Report: Evaluating the Diagnostic Yield of Commercial Gene Panels in Autism.

Researchers looked at genetic tests that companies sell for diagnosing autism. They found these tests don't work very well - they only find a genetic cause in 0.22% to 10% of cases tested. The genes included in different test panels also varied a lot in quality. The study suggests these commercial genetic tests aren't very helpful right now, and broader genetic testing might work better.

This study evaluated the clinical utility of commercial genetic testing panels marketed for autism diagnosis. The researchers analyzed multiple gene panels to assess their diagnostic yield and gene selection quality. Results showed significant variability in diagnostic yields, ranging from 0.22% to 10.02%, indicating that most tests identify genetic causes in fewer than 1 in 10 individuals tested. Gene selection also varied considerably, with overlap with established autism-related genes (SFARI Gene database) ranging from 15.15% to 100%.

The authors concluded that current commercial gene panels have limited clinical utility for autism diagnosis and suggest that broader sequencing approaches may be more appropriate for identifying genetic causes.

Clinicians should be cautious about recommending commercial autism gene panels given their low diagnostic yields and variable quality. Broader genetic sequencing approaches may provide better diagnostic value. Families considering genetic testing should understand the limited likelihood of obtaining definitive results from current commercial panels.

The abstract does not specify sample sizes, methodological details, or which specific commercial panels were evaluated. The study appears to be an analysis of existing panels rather than prospective testing of individuals.

Autism is a prevalent neurodevelopmental condition, highly heterogenous in both genotype and phenotype. This communication adds to existing discussion of the heterogeneity of clinical sequencing tests, "gene panels", marketed for application in autism. We evaluate the clinical utility of available gene panels based on existing genetic evidence. We determine that diagnostic yields of these gene panels range from 0.22% to 10.02% and gene selection for the panels is variable in relevance, here measured as percentage overlap with SFARI Gene and ranging from 15.15% to 100%.

We conclude that gene panels marketed for use in autism are currently of limited clinical utility, and that sequencing with greater coverage may be more appropriate.